Pembrolizumab (Keytruda) is an immune checkpoint inhibitor. Because it revs up the immune system, its side effects are usually immune-related adverse events (irAEs) that can affect almost any organ. These irAEs can occur at any time, including after long-term use, and some can become long‑lasting or even permanent.
How side effects tend to evolve with long-term use
- Most irAEs appear in the first months of treatment, especially 6–12 weeks after starting.
- The risk of new irAEs can persist with ongoing treatment, and a smaller number can appear after stopping the drug.
- Some side effects improve or resolve with treatment (steroids or other immunosuppressants) or with holding/stoppping Keytruda.
- A few adverse effects, especially endocrine ones, may be permanent and require ongoing replacement therapy (e.g., thyroid hormone if hypothyroidism develops; insulin if autoimmune diabetes develops).
Common patterns you may see over time
- Fatigue, rash, itching, and diarrhea are among the more frequent symptoms and can occur at various times.
- Immune-related thyroid problems (hypothyroidism or transient hyperthyroidism) can develop weeks to months in and often require lifelong thyroid therapy if hypothyroidism persists.
- Other endocrine issues (hypophysitis, adrenal insufficiency, new-onset diabetes) can be permanent or require long-term hormone replacement.
- Less common but serious irAEs include pneumonitis (lung), hepatitis (liver), colitis (intestine), nephritis (kidneys), and myocarditis (heart). These can be severe and may require stopping treatment and immunosuppression.
- Skin changes like vitiligo are more common in melanoma patients and can be long-lasting; other rashes or itch may improve with treatment or steroids.
What to monitor and how it’s managed (general guidance)
- Regular labs and check-ins: liver enzymes (AST/ALT), bilirubin, kidney function (creatininine), thyroid tests (TSH, free T4), blood sugar if there are symptoms, and sometimes cortisol if fatigue or other symptoms suggest endocrine issues.
- Report new or worsening symptoms promptly, especially:
- Shortness of breath, persistent cough
- Chest pain
- Severe stomach pain, persistent diarrhea or vomiting
- Jaundice (yellowing eyes/skin), dark urine
- Severe fatigue, confusion, severe dizziness
- Severe or sudden rash, swelling, trouble breathing
- Symptoms suggesting low blood sugar or dehydration
- If a severe irAE is suspected, treatment may involve holding Keytruda and starting corticosteroids or other immune-suppressing therapies. Some irAEs require stopping therapy permanently.
- Endocrine irAEs often require ongoing treatment (e.g., levothyroxine for hypothyroidism, insulin for diabetes) even after Keytruda is stopped.
Practical takeaways
- The risk of side effects from Keytruda is not limited to early treatment; long-term use carries ongoing risk for irAEs, some of which can be permanent.
- Most people tolerate Keytruda well, but a minority develop serious irAEs that require medical care.
- Management is highly individualized and depends on which organ is affected and how severe the irAE is.
If you’d like, tell me your cancer type, treatment plan, and how long you’ve been on Keytruda. I can tailor this to more specific risks and monitoring, and help you think about questions to discuss with your oncologist. This information is general and not a substitute for medical advice. If you’re currently experiencing symptoms, contact your healthcare provider promptly.